In addition to MedImmune's vast internal discovery capabilities, we actively
seek external partnering for licensing and collaboration agreements to develop
potential targets and technologies.
A sample list of our current Partnering includes:
Abbott
In 1993, Cambridge Antibody Technologies (now a part of MedImmune and
AstraZeneca) and BASF Pharma (Knoll) now part of Abbott
entered into a broad research collaboration to identify and develop human
monoclonal antibody therapeutics. The first two targets identified under this
collaboration were TNFalpha and IL-12. MedImmune, in collaboration with Abbott,
isolated and optimized antibodies against these targets (which became HUMIRA®
[adalimumab] and ABT-874, respectively) with Abbott having responsibility for
their development and marketing. HUMIRA® has now been approved and
marketed as a treatment for rheumatoid arthritis, juvenile rheumatoid
arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and
Crohn's disease, worldwide.
BioWa, Inc., 2006, development initially focused on developing
BIW-8405, a monoclonal antibody for patients with asthma.
Crucell, 2007, development of new antibodies for the treatment
and prevention of hospital-acquired bacterial infection.
Genaera Corporation, 2001, research collaboration and an
exclusive licensing agreement to develop and commercialize antibodies to
prevent symptoms of asthma and other respiratory diseases.
GlaxoSmithKline (GSK), 1997 (revised in 2005), collaboration to
develop a vaccine against human papillomavirus (HPV) to prevent cervical
cancer.
HGS
1) 1999: identification of antibodies against target proteins proprietary to
HGSI, the first of which was the protein
BLyS (or B-lymphocyte stimulator) that subsequently lead to the
isolation and optimization of the MAb known as LymphoStat-B®.
2) 2000: collaboration to identify antibodies against HGSI's proprietary target
proteins that lead to two human monoclonal antibody drug candidates: HGS-ETR1
and HGS-ETR2 (anti-TRAIL Receptor-1 and anti-TRAIL Receptor-2, respectively)
for the treatment of cancer.
Medarex, Inc., 2004, collaboration agreement to develop and
commercialize antibodies for treatment of autoimmune diseases.
Pfizer, 1999, collaboration with Pharmacia (now Pfizer) for the
development of human monoclonal antibody therapeutics across a number of
disease areas but with a primary focus in cancer.
Sidec Technologies AB, 2007, technology expected to help
MedImmune better understand the production process of its vaccine candidates.
United States Government Partnering
-
National Institutes of Health, 2006, six-year Cooperative
Research and Development Agreement (CRADA) with the National Institute of
Allergy and Infectious Diseases (NIAID) to increase the pipeline for RSV PIV-3
vaccine candidates. CRADA's goal is to develop live, attenuated vaccines to
prevent lower respiratory illness caused by RSV, HPIV3, HPIV1, HPIV2, and HMPV.
-
U.S. Department of Health and Human Services (DHHS)*, 2006,
development of a cell culture manufacturing process for an LAIV. National goal
is to be able to vaccinate the entire U.S. population within 6 months of a
pandemic declaration; 2007, expansion of existing egg-based LAIV manufacturing
facilities to enable manufacturing of 50 million doses within 12 months of a
declaration of pandemic.
* These projects are funded in whole or in part with federal funds from the
Office of the Assistant Secretary for Preparedness and Response (ASPR),
Biomedical Advanced Research and Development Authority, under Contract Nos.
HHSO100200600010C and HHSO100200700036C. The total Federal program funding for
these contracts is $221,379,570, representing approximately 92% of the total
amount of the projects. The remaining 8% of the total amount for the projects
is anticipated to be financed by nongovernmental sources. The content of this
publication does not necessarily reflect the views or policies of the
Department of Health and Human Services, nor does the mention of trade names,
commercial products, or organizations imply endorsement by the U.S. Government.